Surgery
Effectiveness of Surgical Treatment on Survival of Patients with Malignant Pleural Mesothelioma
Cancers 2025 July 16 [Link] Renata Báez-Saldaña, María Esther Marmolejo-Torres, Marco Antonio Iñiguez-García, Aída Jiménez-Corona, Juan Alberto Berrios-Mejía Abstract Background: The benefit of surgery for malignant pleural mesothelioma is highly debated, as few robust clinical trials show its effectiveness. Objective: To examine the long-term survival of patients with malignant pleural mesothelioma who underwent surgical treatment…
Read MoreNeoadjuvant immunotherapy in a solitary, isolated peritoneal mesothelioma involving the abdominal wall: a case report
Immunotherapy 2025 July [Link] Parsa Charkhchi, Ryan Le, Taryn E Cazzolli, Raina R Flores, Roberto A Martinez, Supreet Kaur, Mio Kitano Abstract Mesothelioma is a rare neoplasm with a minority of cases originating from the peritoneum. Patients are generally treated with a combination of cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, and various systemic therapies. In recent…
Read MoreA giant peritoneal mesothelioma extending to the pelvic floor: A case report and review of the literature
Journal of Cancer Research and Therapeutics 2025 April 1 [Link] Mathew Thomas, Harikrishnan Nandakumar, Parth Sampat, Stephen Graziano Abstract Malignant peritoneal mesothelioma (MPM) is a rare malignancy originating from the peritoneal serosa and is the second most common site of mesothelioma after the pleura. Localized disease presents as a focal circumscribed mass, whereas diffuse disease…
Read MoreProlonged Survival in Mesothelioma Patients Without Surgical Resection: A National Cancer Database Analysis
The Annals of Thoracic Surgery 2025 June 28 [Link] Peter L Zhan, Maureen E Canavan, Justin M Bader, Daniel J Boffa, Benjamin J Resio, Gavitt A Woodard Abstract Background: The Mesothelioma and Radical Surgery 2 (MARS 2) trial demonstrated no survival benefit from cytoreductive surgical resection over chemotherapy alone in resectable pleural mesothelioma. Using the…
Read MoreLong term side effects after volumetric modulated arc therapy to the pleura in patients with malignant pleural mesothelioma
Lung Cancer 2025 August [Link] Vishruta Dumane, Juliana Runnels, Raja Flores, Andrea Wolf, Weijia Fu, Madhu Mazumdar, Thomas Marron, Jorge Gomez, Kenneth Rosenzweig Abstract Purpose: Lung-sparing pleurectomy/decortication (P/D) is the primary surgical approach for malignant pleural mesothelioma (MPM), and combining it with other therapies enhances patient outcomes.This report presents the extended follow-up results of MPM…
Read MoreClinical and Pathologic Phenotyping of mesotheliomas developing in carriers of Germline BAP1 Mutations
Journal of Thoracic Oncology 2025 June 27 [Link] Michele Carbone, Michael Minaai, Muaiad Kittaneh, Thomas Krausz, Markku M Miettinen, Qiang Pan Hammarström, Lennart Hammarström, Hassan Abolhassani, Ian Pagano, Ronghui Xu, Flavia Novelli, Giovanni Gaudino, Sandra Pastorino, Kavita Y Sarin, Robert T Ripley, Harvey I Pass, David S Schrump , Haining Yang Abstract Introduction: Mesothelioma is…
Read MoreImpact of Multimodal Surgical Resection and Personalized Targeted Therapy on Survival Outcomes in Early-Stage Malignant Pleural Mesothelioma: A Meta-Analysis
Cureus 2025 May 22 [Link] Alexis Quetzalcoatl Vega Morales, Jorge Luis Rivera Gastelum, Alfonso J Massé Ponce, Alexis Agustin A Dunay Silva, Emiliano Banda Dávila, Andrea Virginia Rivera Aguirre, Odalys Brigitte Villares Santillán, Michael David Naranjo Venegas Abstract Malignant pleural mesothelioma (MPM) is an aggressive malignancy with limited evaluates the efficacy and safety of these…
Read MoreCharacteristics of Long-Term Survivors With Peritoneal Mesothelioma – Insights From the National Cancer Database
The American Surgeon 2025 June 17 [Link] Himani Bhatt, Deep P Vakil, Luis Quintero, Monique Motta, Maria Vashchenko, Bettsy Rodriguez, Shenae K Samuels, Kumar Jayant, Jonathan Magloire, Christopher J Gannon, Omar H Llaguna Abstract Introduction: Peritoneal mesothelioma (PM) is a rare cancer associated with high mortality. No studies exist using the National Cancer Database (NCDB)…
Read MoreNational Guidelines for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Peritoneal Malignancies: A Worldwide Systematic Review and Recommendations of Strength Analysis
Annals of Surgical Oncology 2025 August [Link] Marco Tonello, Carola Cenzi, Elisa Pizzolato, Manuela Martini, Pierluigi Pilati, Antonio Sommariva Abstract Background: National guidelines (GLs) for surgical cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of peritoneal malignancies (PMs) vary across countries, scientific societies, and government agencies. This study aimed to systematically review and…
Read MoreClinical Significance of Tumor-Infiltrating Lymphocytes in Malignant Peritoneal Mesothelioma: A Single-Center Study of 143 Cases
Annals of Surgical Oncology 2025 July [Link] He-Liang Wu, Rui Yang, Xin-Li Liang, Ru Ma, Yan-Dong Su, Zhi-Ran Yang, Yu-Run Cui, Xue-Mei Du, Yi-Tong Liu, Yan Li Abstract Background: Malignant peritoneal mesothelioma (MPM) is a rare malignant tumor with high mortality rate and extremely poor prognosis. The tumor immune microenvironment, particularly tumor-infiltrating lymphocytes (TILs), plays…
Read More